RE: Characterization of Factors Associated With Disease Severity in Adults Hospitalized With Respiratory Viral Infection: The Universal Study21 May 2024 13:40
Interesting study, it was looking at critically ill patients in ICU and took a blood sample very late on in disease progression. At this stage as the study showed it made no difference if people had Auto Ab's or not in mortality outcomes.
Interestingly they speculate that the similar clinical picture between patients with positive and negative auto-Abs might be explained by a common mechanism, i.e., an impaired type I IFN production or response. Additionally they speculated our corticosteroids will have had an impact to results.
With Universal taking an earlier blood sample (at admission) and comparing Auto Ab's at this stage is what SNG will need to see. At an earlier stage of disease is there a difference between patients with positive and negative auto-Abs in disease progression and the length of hospital stays? If we see a difference then we have our cohort for a P2 trial.
Essentially a rough idea
1) Patient admitted to hospital with exacerbated viral illness.
2) Screen for at risk people ie Age, comorbidities.
3) Take blood test and check for Auto-Abs (easy enough to do with standard assay)
4) If positive give SNG001 to most likely people to benefit from drug.
5) As a trial endpoint hope there is a reduction in hospital stay duration and the recovery to normal activities quicker. (Requiring less follow up appointments with a Dr or another hospital stay) - Obvious cost benefit means you can justify a good drug price.
Sign In
Follow the stocks
